UNCY

Unicycive Therapeutics, Inc. UNCY

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $1.0M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Net income

$-1.72M

Quarter to Jun 30

Free cash flow

$-7.61M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$54.56M total
BlackRock, Inc.
$6.63M+3836.7%
Nantahala Capital Management, LLC
$6.57M+49.2%
VANGUARD CAPITAL MANAGEMENT LLC
$5.03M+32.0%
Octagon Capital Advisors LP
$4.69M0.0%
GEODE CAPITAL MANAGEMENT, LLC
$2.65M+176.8%
Vivo Capital, LLC
$2.58M-69.3%
MARSHALL WACE, LLP
$2.57M+253.6%
Logos Global Management LP
$2.22M0.0%
STATE STREET CORP
$2.11M+462.5%
Diametric Capital, LP
$1.75M+365.6%
J. Goldman & Co LP
$1.54MNew
DIADEMA PARTNERS LP
$1.42M+186.3%
MILLENNIUM MANAGEMENT LLC
$1.27M-80.6%
Dauntless Investment Group, LLC
$1.00M+45.5%
CITIGROUP INC
$856.6KNew
NORTHERN TRUST CORP
$853.3K+406.2%
VANGUARD PORTFOLIO MANAGEMENT LLC
$793.5KNew
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$750.6K-19.7%
Jump Financial, LLC
$717.6KNew
VANGUARD FIDUCIARY TRUST CO
$698.6K+47.4%
GOLDMAN SACHS GROUP INC
$681.5K+436.3%
DIMENSIONAL FUND ADVISORS LP
$678.0K0.0%
Seven Fleet Capital Management LP
$521.1K+85.6%
Caption Management, LLC
$515.9KNew
MORGAN STANLEY
$514.2K-41.7%
See all 80 institutional holders →
Reading the latest SEC filing…

Key Metrics

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/UNCY

Earnings Per Share

13fpro.ai/company/UNCY

Loading ratio trend…

UNCY key financials by period

Reported revenue, net income and operating margin by fiscal year, from Unicycive Therapeutics, Inc.'s annual filings on SEC EDGAR.

Unicycive Therapeutics, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2023$675.0K$-30.5M—
FY 2022$951.0K$-18.1M—
Source: UNCY filings on SEC EDGAR →

UNCY insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Unicycive Therapeutics, Inc. (UNCY): stock profile, AI score and financials

Unicycive Therapeutics, Inc. (UNCY) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. UNCY is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $1.0m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q2 2026), Unicycive Therapeutics, Inc. reports net income of $-1.7M, free cash flow of $-7.6M. Top institutional holders of UNCY by reported 13-F value include BlackRock, Nantahala Capital Management, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. UNCY trades on the Nasdaq exchange and files with the SEC under CIK 1766140. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate UNCY daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Unicycive Therapeutics, Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1766140 →